JP2010523497A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523497A5
JP2010523497A5 JP2010501235A JP2010501235A JP2010523497A5 JP 2010523497 A5 JP2010523497 A5 JP 2010523497A5 JP 2010501235 A JP2010501235 A JP 2010501235A JP 2010501235 A JP2010501235 A JP 2010501235A JP 2010523497 A5 JP2010523497 A5 JP 2010523497A5
Authority
JP
Japan
Prior art keywords
triazolo
pyrrolo
furan
ethyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010501235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523497A (ja
Filing date
Publication date
Priority claimed from US12/056,403 external-priority patent/US7691869B2/en
Application filed filed Critical
Publication of JP2010523497A publication Critical patent/JP2010523497A/ja
Publication of JP2010523497A5 publication Critical patent/JP2010523497A5/ja
Withdrawn legal-status Critical Current

Links

JP2010501235A 2007-03-30 2008-03-28 アデノシンａ２ａ受容体拮抗薬 Withdrawn JP2010523497A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90910607P 2007-03-30 2007-03-30
US12/056,403 US7691869B2 (en) 2007-03-30 2008-03-27 Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
US12/056,423 US7723343B2 (en) 2007-03-30 2008-03-27 Adenosine A2A receptor antagonists
PCT/US2008/058544 WO2008121748A2 (en) 2007-03-30 2008-03-28 Adenosine a2a receptor antagonists

Publications (2)

Publication Number Publication Date
JP2010523497A JP2010523497A (ja) 2010-07-15
JP2010523497A5 true JP2010523497A5 (https=) 2011-05-12

Family

ID=39795488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010501235A Withdrawn JP2010523497A (ja) 2007-03-30 2008-03-28 アデノシンａ２ａ受容体拮抗薬

Country Status (12)

Country Link
US (2) US7723343B2 (https=)
EP (1) EP2129220A4 (https=)
JP (1) JP2010523497A (https=)
KR (1) KR20100014397A (https=)
CN (1) CN101652067A (https=)
AU (1) AU2008232690A1 (https=)
BR (1) BRPI0808438A2 (https=)
CA (1) CA2680075A1 (https=)
IL (1) IL201234A0 (https=)
MX (1) MX2009010223A (https=)
NZ (1) NZ578720A (https=)
WO (1) WO2008121748A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906518B2 (en) * 2006-06-27 2011-03-15 Cbt Development Limited Therapeutic compounds
CN104592231A (zh) 2008-06-10 2015-05-06 Abbvie公司 新的三环化合物
CA2750577A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
RU2711869C3 (ru) 2009-12-01 2022-02-02 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
PH12012501000A1 (en) 2009-12-01 2013-02-11 Abbvie Inc Novel tricyclic compounds
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
AU2011306358B2 (en) * 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
WO2012149280A2 (en) * 2011-04-29 2012-11-01 Abbott Laboratories Novel tricyclic compounds
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
CN109641911B (zh) * 2016-08-19 2023-02-21 百时美施贵宝公司 seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法
AU2018246355B2 (en) * 2017-03-30 2021-12-09 iTeos Belgium SA 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers
WO2020112700A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en) 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
KR100687954B1 (ko) 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
IL161716A0 (en) 2001-11-30 2004-09-27 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
AU2003245380A1 (en) 2002-05-30 2003-12-19 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
US20060128694A1 (en) 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
EP1934227B1 (en) 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a

Similar Documents

Publication Publication Date Title
JP2010523497A5 (https=)
KR102021159B1 (ko) 트리시클릭 헤테로시클릭 화합물 및 jak 저해제
US9227971B2 (en) Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
US8227472B2 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
EP3468971B1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EP2608669B1 (en) NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
RU2431635C2 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
AU2010310595B2 (en) Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
EP2200440B1 (en) Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
EP1700856B1 (en) Thiazole derivative
KR20100014397A (ko) 아데노신 에이투에이 수용체 길항제
JP2006518370A5 (https=)
JP2011529504A5 (https=)
JP2004507442A5 (https=)
JP2009528389A5 (https=)
RS57741B1 (sr) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
WO2012027239A1 (en) NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
JP2014511355A5 (https=)
JP2019537590A5 (https=)
Fatahala et al. Synthesis strategies and medicinal value of pyrrole and its fused heterocyclic compounds
US20100280023A1 (en) Thiazole derivatives
CA2510170A1 (en) 3-substituted-4-pyrimidone derivatives
Mohamed et al. Synthesis strategies and biological value of pyrrole and pyrrolopyrimidine
CN102316871B (zh) [1，2，4]噻二嗪1，1-二氧化合物
EP2736338A1 (en) FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS